Instituto Portugues De Oncologia De Lisboa Francisco Gentil E.P.E.

At the Instituto Portugues De Oncologia De Lisboa Francisco Gentil E.P.E., most studies focus on cancer research across solid tumors and blood cancers. The trials are designed to test new treatment options, compare them with current standards, and improve outcomes for people with difficult-to-treat cancers.

• High-risk large B-cell lymphoma and diffuse large B-cell lymphoma, with studies aiming to improve first-line treatment effectiveness
• Melanoma, including research on adjuvant therapy and treatment for unresectable or metastatic disease
• Breast cancer, especially HER2-low and HER2 IHC 0 disease, with trials exploring newer targeted options
• Esophageal carcinoma, where treatment is being evaluated alongside standard chemoradiotherapy

Overall, this oncology program is centered on finding more effective and durable therapies for advanced and high-risk cancers.

Clinical research in hematologic diseases at this hospital-based oncology center includes both aggressive lymphomas and disorders of blood formation. The main goal is to improve survival, disease control, and supportive care for patients with complex blood cancers and marrow conditions.

• Acute lymphoblastic leukemia in infants, with studies focused on improving outcomes in newly diagnosed disease
• Diffuse Large B-Cell Lymphoma (DLBCL) and related high-risk lymphoma subtypes, testing added immunotherapy approaches
• Relapsed or refractory marginal zone lymphoma, with research comparing new combination strategies against physician-selected care
• Myelodysplastic syndrome (MDS), where trials are evaluating better treatment for anemia and transfusion dependence

These studies reflect a strong interest in both frontline and relapsed blood cancer care, as well as symptom relief in chronic marrow disorders.

Within digestive system oncology, the site is involved in research for esophageal carcinoma. The trial activity here is aimed at improving the effectiveness of treatment for patients receiving standard cancer therapy, with a focus on better disease control and longer-lasting responses.

• Esophageal carcinoma, studied to assess whether adding a new immune-based treatment can improve outcomes
• Head-to-head treatment evaluation alongside established chemoradiotherapy to strengthen current care approaches
• Oncology care optimization for a hard-to-treat gastrointestinal cancer population

This area highlights the site’s broader effort to refine treatment for advanced cancers affecting the digestive tract.

The Medical Oncology department also supports studies in melanoma and cutaneous squamous cell carcinoma. These trials are looking at whether newer immune-based or adjuvant approaches can reduce recurrence and improve long-term control after treatment.

• Unresectable or metastatic melanoma, with trials comparing new immunotherapy options to established treatment
• Resectable high-risk locally advanced cutaneous squamous cell carcinoma, where adjuvant therapy is being evaluated to lower recurrence risk
• Resected melanoma, with research focused on preventing the cancer from returning

These studies show a clear emphasis on strengthening immunotherapy strategies in both advanced and high-risk skin cancers.

Across several disease areas, the research portfolio at Instituto Portugues De Oncologia De Lisboa Francisco Gentil E.P.E. is centered on immunotherapy and targeted treatment. The trials are intended to improve progression-free survival, event-free survival, overall survival, and recurrence control.

• CAR-T and bispecific antibody approaches in lymphoma
• Immune checkpoint therapy in melanoma, esophageal cancer, and skin cancer
• Novel targeted antibody-drug conjugates in breast cancer
• Supportive and disease-modifying therapies for blood disorders such as MDS

With 13 trials and a large investigator network, the site is contributing to the evaluation of advanced cancer therapies across multiple tumor types.